Search research articles
Contact Us
Filters
Showing results (231-240 of 264) with videos related to
Page
of 27
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 30, 2016
Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial
Karin Ribi, Weixiu Luo, Jürg Bernhard, et al.
Nature
|
September 6, 2023
Spatial predictors of immunotherapy response in triple-negative breast cancer
Xiao Qian Wang, Esther Danenberg, Chiun-Sheng Huang, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 15, 2023
Ten-year survival of neoadjuvant dual HER2 blockade in patients with HER2-positive breast cancer
Paolo Nuciforo, John Townend, Martine J Piccart, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 26, 2026
Role of ctDNA in predicting the outcome of patients with hormone receptor-positive, HER2-negative advanced breast cancer treated with first-line ribociclib and letrozole: BioItaLEE trial
Giampaolo Bianchini, Luca Malorni, Roberta Caputo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 30, 2021
Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2- Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial
Yen-Shen Lu, Seock-Ah Im, Marco Colleoni, et al.
British Journal of Cancer
|
January 18, 2020
Correction: Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial
Karin Ribi, Weixiu Luo, Marco Colleoni, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 23, 2024
The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer
Matteo Dugo, Chiun-Sheng Huang, Daniel Egle, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 15, 2022
Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials
Olivia Pagani, Barbara A Walley, Gini F Fleming, et al.
The Lancet. Oncology
|
May 29, 2018
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
Debu Tripathy, Seock-Ah Im, Marco Colleoni, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 2, 2021
Preservation of quality of life in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer treated with tucatinib or placebo when added to trastuzumab and capecitabine (HER2CLIMB trial)
Volkmar Mueller, Andrew Wardley, Elisavet Paplomata, et al.
Page
of 27
Search research articles
Search
Showing results (231-240 of 264) with videos related to
Sort By:
Page
of 27
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 30, 2016
Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial
Karin Ribi, Weixiu Luo, Jürg Bernhard, et al.
Nature
|
September 6, 2023
Spatial predictors of immunotherapy response in triple-negative breast cancer
Xiao Qian Wang, Esther Danenberg, Chiun-Sheng Huang, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 15, 2023
Ten-year survival of neoadjuvant dual HER2 blockade in patients with HER2-positive breast cancer
Paolo Nuciforo, John Townend, Martine J Piccart, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 26, 2026
Role of ctDNA in predicting the outcome of patients with hormone receptor-positive, HER2-negative advanced breast cancer treated with first-line ribociclib and letrozole: BioItaLEE trial
Giampaolo Bianchini, Luca Malorni, Roberta Caputo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 30, 2021
Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2- Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial
Yen-Shen Lu, Seock-Ah Im, Marco Colleoni, et al.
British Journal of Cancer
|
January 18, 2020
Correction: Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial
Karin Ribi, Weixiu Luo, Marco Colleoni, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 23, 2024
The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer
Matteo Dugo, Chiun-Sheng Huang, Daniel Egle, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 15, 2022
Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials
Olivia Pagani, Barbara A Walley, Gini F Fleming, et al.
The Lancet. Oncology
|
May 29, 2018
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
Debu Tripathy, Seock-Ah Im, Marco Colleoni, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 2, 2021
Preservation of quality of life in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer treated with tucatinib or placebo when added to trastuzumab and capecitabine (HER2CLIMB trial)
Volkmar Mueller, Andrew Wardley, Elisavet Paplomata, et al.
Page
of 27